The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Rituximab, gemcitabine, cisplatin, and methylprednisolone (R-GEM-P) in treatment of relapsed diffuse large B-cell lymphoma (DLBCL).
Sarah Rachel Barton
No relevant relationships to disclose
Eliza Anne Hawkes
Other Remuneration - Roche
David Cunningham
Consultant or Advisory Role - Amgen (U); Roche (U)
Research Funding - Amgen; Celgene; Merck Serono; Novartis; Roche; Sanofi
Clare Peckitt
No relevant relationships to disclose
Sue Chua
No relevant relationships to disclose
Andrew Wotherspoon
No relevant relationships to disclose
Ayoma Attygalle
No relevant relationships to disclose
Alan Horwich
No relevant relationships to disclose
Claire E. Dearden
Consultant or Advisory Role - Roche
Honoraria - Roche
Mike Potter
No relevant relationships to disclose
Ian Chau
No relevant relationships to disclose